In summary, we found that ATP1A3 might be a potential target of CS‐6 in GBM and that regulating ATP1A3 could significantly impact the anti‐glioma efficacy of CS‐6 and its combination with TMZ. The gene discussed is ATP1A3; the disease is central nervous system cancer.